HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Arvind K. Agnihotri David C. McGiffin Mark F. O'Brien Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Agnihotri, A. K. Articles by O'Brien, M. F. Search for Related Content PubMed PubMed Citation Articles by Agnihotri, A. K. Articles by O'Brien, M. F.

J Thorac Cardiovasc Surg 1995;110:1708-1724
© 1995 Mosby, Inc.

SURGERY FOR ACQUIRED HEART DISEASE

THE PREVALENCE OF INFECTIVE ENDOCARDITIS AFTER AORTIC VALVE REPLACEMENT

Birmingham, Ala. and Brisbane, Queensland, Australia

Supported in part by a grant from The National Heart Foundation of Australia, G90B2990.

Address for reprints: David C. McGiffin, MD, University of Alabama at Birmingham, 619 19th St. South, Birmingham, AL 35294.

Abstract

Replacement valve endocarditis occurred in 3.7% of 2443 patients who underwent primary or redo aortic valve replacements at The Prince Charles Hospital between December 31, 1969, and January 1, 1992, based on a cross-sectional follow-up in 1992 which was 98.8% complete. Because some patients had re-replacements during the study period, a total of 2686 operations were considered for analysis. A variety of replacement devices were used, including 571 allografts (21%), 1152 xenografts (43%), and 880 mechanical valves (36%). Insertion of an allograft valve resulted in a constant risk of endocarditis which, by multivariable hazard function analysis, negated the effect of any early-phase risk factors (p <0.0001). With other replacement devices, the risk of infection peaked early after operation (9 weeks) and then gave way to a constant risk. Compared with the risk associated with allograft valves, constant risk was higher when the replacement device was a Carpentier-Edwards xenograft (n = 1021, p = 0.02) and lower when a St. Jude Medical mechanical valve was used (n = 505, p = 0.05). In nonallograft recipients, the presence of active preoperative endocarditis (p <0.0001) or a concomitant synthetic aortic root replacement (p = 0.0006) increased the magnitude of the early peaking risk. Regardless of replacement device, constant risk was increased in patients with renal dysfunction (p = 0.01), in younger patients (p <0.0001), and in those with active or healed preoperative endocarditis (p = 0.04). When preoperative endocarditis was caused by Staphylococcus aureus, risk was higher than when it was caused by other organisms (p = 0.04). A culture-positive postoperative wound infection was associated with increased risk of replacement valve infection (p <0.001) and when it occurred, the same organism was usually responsible (86%). Identification of patients at increased risk for replacement valve infection may lead to reduced morbidity through strategies such as selective use of replacement devices and antimicrobial prophylaxis. (J THORAC CARDIOVASC SURG 1995;110:1708-24)

This article has been cited by other articles:

				S. Pagni, A. Dempsey, and E. H. Austin III Tricuspid and aortic valve and ventricular septal defect endocarditis: an unusual presentation of acute q Fever. Ann. Thorac. Surg., December 1, 2009; 88(6): 2027 - 2029. [Abstract] [Full Text] [PDF]

				S. C. Stamou, G. Petterson, and A. M. Gillinov Surgical Treatment of Mitral Valve Endocarditis Card. Surg. Adult, January 1, 2008; 3(2008): 1069 - 1078. [Full Text]

				J. P.A. Puvimanasinghe, J. J.M. Takkenberg, M. J.C. Eijkemans, E. W. Steyerberg, L. A. van Herwerden, G. L. Grunkemeier, J. D. F. Habbema, and A. J.J.C. Bogers Prognosis After Aortic Valve Replacement With the Carpentier-Edwards Pericardial Valve: Use of Microsimulation Ann. Thorac. Surg., September 1, 2005; 80(3): 825 - 831. [Abstract] [Full Text] [PDF]

				E. Mylonakis and S. B. Calderwood Infective Endocarditis in Adults N. Engl. J. Med., November 1, 2001; 345(18): 1318 - 1330. [Full Text] [PDF]

				T. Mihaljevic, J. G. Byrne, L. H. Cohn, and S. F. Aranki Long-term results of multivalve surgery for infective multivalve endocarditis Eur. J. Cardiothorac. Surg., October 1, 2001; 20(4): 842 - 846. [Abstract] [Full Text] [PDF]

				R. G. Seipelt, J. F. Vazquez-Jimenez, I. M. Seipelt, A. Franke, K. Chalabi, F. A. Schoendube, and B. J. Messmer The St. Jude ""Silzone"" valve: midterm results in treatment of active endocarditis Ann. Thorac. Surg., September 1, 2001; 72(3): 758 - 762. [Abstract] [Full Text] [PDF]

				A. M. Gillinov, R. Diaz, E. H. Blackstone, G. B. Pettersson, J. F. Sabik, B. W. Lytle, and D. M. Cosgrove III Double valve endocarditis Ann. Thorac. Surg., June 1, 2001; 71(6): 1874 - 1879. [Abstract] [Full Text] [PDF]

				M. R. Moon, D. C. Miller, K. A. Moore, P. E. Oyer, R. S. Mitchell, R. C. Robbins, E. B. Stinson, N. E. Shumway, and B. A. Reitz Treatment of endocarditis with valve replacement: the question of tissue versus mechanical prosthesis Ann. Thorac. Surg., April 1, 2001; 71(4): 1164 - 1171. [Abstract] [Full Text] [PDF]

				O. Lund, S. L. Nielsen, H. Arildsen, L. B. Ilkjaer, and H. K. Pilegaard Standard aortic St. Jude valve at 18 years: performance profile and determinants of outcome Ann. Thorac. Surg., May 1, 2000; 69(5): 1459 - 1465. [Abstract] [Full Text] [PDF]

				O. Lund, V. Chandrasekaran, R. Grocott-Mason, H. Elwidaa, R. Mazhar, A. Khaghani, A. Mitchell, C. Ilsley, and M. H. Yacoub PRIMARY AORTIC VALVE REPLACEMENT WITH ALLOGRAFTS OVER TWENTY-FIVE YEARS: VALVE-RELATED AND PROCEDURE-RELATED DETERMINANTS OF OUTCOME J. Thorac. Cardiovasc. Surg., January 1, 1999; 117(1): 77 - 91. [Abstract] [Full Text] [PDF]